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Skin metastases often represent a major therapeutic problem in
oncology, especially in patients with metastases no longer
amenable to standard therapeutic measures such as surgery, radia-
tion or systemic chemotherapy (Unger et al, 1990, 1992). On the
other hand, treatment is complicated in situations when skin
metastases progress despite response to systemic treatment at
other sites (mixed response). The visibility of the tumours is often
an additional aggravating factor in the patients￿ psychological situ-
ation. Topical administration of a cytotoxic drug could offer possi-
bilities for local treatment with the additional advantage of
avoiding the risk of major systemic toxicity.
Miltefosine (hexadecylphosphocholine, He-PC) is an alkyl-
phosphocholine with proven cytotoxicity in diverse series of
rodent and human cell lines (Eibl et al, 1986; Unger et al, 1989)
(Figure 1). In vivo, miltefosine has shown anti-tumour activity
against chemically induced rat mammary tumours as well as
human breast carcinomas (Hilgard et al, 1988; Fichtner et al,
1994). Unlike most other anti-tumour substance, alkylphospho-
cholines do not attack the cell nucleus but are active at the level of
the cell membrane (Eibl and Unger, 1990; Unger and Eibl, 1991).
Miltefosine is thought to exert its cytotoxic action predominantly
by interacting with the cell membrane components that are linked
to phospholipid turnover and membrane signal transduction
(Hilgard et al, 1993; Berkovic et al, 1995; Goppelt-Struebe and
Winter, 1995). As a result, miltefosine inhibits protein kinase C,
which induces cell differentiation (Hilgard et al, 1989). Verweij
and others performed a series of phase I and phase II studies with
orally administered miltefosine in soft tissue sarcoma, colorectal
cancer and squamous cell head and neck cancer patients but,
unfortunately, no significant activity was found (Verweij et al,
1992, 1993a, 1993b; Planting et al, 1993). Nausea and vomiting
appeared to be dose-limiting and some patients developed a
reversible renal dysfunction.
For topical application, however, miltefosine is a suitable candi-
date because it can penetrate the skin, although not to an extent
causing systemic side-effects. It is pharmaceutically formulated in a
mixture of water and 1-O-alkylglycerols, amphiphilic molecules
that can change the permeability of membranes as shown by the
penetration of cytostatics across the blood—brain barrier (Unger et
al, 1984; Eibl and Unger, 1990). Moreover, alkylglycerols with
chain lengths > C10 have been shown to possess anti-tumour
activity (Ando et al, 1972). Miltefosine in this formulation appeared
to be effective topically in the treatment of some cutaneous
lymphomas and in progressive skin metastases from breast cancer
(Unger et al, 1988; Dummer et al, 1993; Clive and Leonard, 1997).
The recommended dose for topical application resulting from a
phase I clinical trial with dose-escalation in breast cancer patients
was 60 mg ml—1 (a miltefosine 6% solution), the quantity of solution
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being applied according to the size of the affected area. No systemic
side-effects were observed and the dose-limiting toxicity at
80 mg ml—1 was erythema of the non-pretreated skin, which was
reversible at 60 mg ml—1 (Unger et al, 1992). In this paper we report
the results of a phase II clinical trial performed in our Institute with
topically applied miltefosine in patients with skin-metastasized
breast cancer.
PATIENTS AND METHODS
Patient population
Patients were eligible if they had a histologically verified breast
carcinoma with progressive skin metastases amenable to topical
treatment without concomitant systemic anti-tumour therapy. There
were no restrictions on volume, depth or ulceration. Previous
chemotherapy or radiotherapy was accepted as long as the last
administration was at least 4 weeks before the study entry, or 6
weeks in case of pretreatment with nitrosourea or mitomycin C. All
patients had a performance status † 2 (WHO) and an estimated life
expectancy of ‡ 3 months. Further inclusion criteria were a baseline
number of thrombocytes ‡ 100 ´109l—1, leukocytes ‡ 2.5 ´109l—1 and
transaminases † 4 times the upper limit of reference range. The
study protocol was reviewed and approved by the Ethics Committee
of the Institute and all patients gave written informed consent.
Treatment plan and study design
A 6% solution of miltefosine in a defined mixture of 3-alkoxy-
propyleneglycols (glycerolethers) (Miltex¤, ASTA Medica AG,
Frankfurt, Germany) was applied once daily for the first week and,
if tolerated, twice daily thereafter. The solution was applied to, and
gently rubbed into, the lesion and involved skin with the inclusion
of a 3 cm margin of surrounding normal skin. The total dose
applied therefore varied according to the size of area treated. A
mixture of 10% vaseline was applied in addition to the miltefosine
lotion to prevent or improve desquamation. The anticipated
minimum treatment duration was 8 weeks. In cases of a complete
remission, therapy was continued for another 4 weeks and then
discontinued, while in cases of no change or partial remission,
therapy continued until relapse. After a pretreatment assessment to
verify eligibility for the trial patients were reassessed by clinical
history, physical examination and laboratory investigations after
1 week, 2 weeks, and every 4 weeks thereafter while on treatment,
and at the end of treatment.
Response criteria
Response was evaluated by measurement of indicator lesions
together with a photograph every 4 weeks and at the end of treat-
ment. Patients who had a complete disappearance of all treated
lesions for at least 4 weeks were considered to have experienced a
complete response. A partial response was defined as an estimated
decrease in tumour size of 50% or more for at least 4 weeks. Stable
disease included an estimated decrease of lesions of less than 50%
and an estimated increase of lesions of less than 25%. Progressive
disease was defined as an increase in tumour size of 25% or
more. New lesions outside the treated area were not considered as
evidence of (local) progression and subsequent inclusion of new
(non-indicator) lesions after a response in the primary treated area
was allowed.
Other criteria
Toxicity was classified and graded according to WHO criteria.
Response duration was calculated between start of treatment and first
observation of progression or treatment failure (time to progression).
RESULTS
Patients
Thirty-four female patients with a primary diagnosis of breast
cancer were entered into the trial. One patient did not return to
hospital after the pretreatment assessment and has therefore been
excluded from further analyses. Of the remaining 33 patients, the
median age was 57 years with a range of 30—90 years. All had
previously received extensive tumour-specific treatment. Table 1
summarizes their main characteristics. Skin lesions were classified
as either ￿indicator lesions￿ (lesions located in the started area of
miltefosine treatment) or ￿non-indicator lesions￿ (later extensions
of the initial treatment area). Twenty-two of the 33 patients (67%)
had 1—3 indicator lesions and 11 patients (33%) had more than 3
lesions. The 33 patients were treated with miltefosine for 1—68
weeks and the median treatment duration was 10 weeks. Fourteen
patients (42%) were treated for more than 12 weeks. Local
progression in the treated area was the most frequent reason to
stop further miltefosine treatment (19 patients). Other reasons
were systemic progression (nine), local progression outside treated
area (four), loss to follow-up (two), adverse skin reactions (two),
refusal (one) and poor drug tolerance (one).
Toxicity
All 33 patients were evaluated for toxicity. Adverse drug reactions
(ADRs) were mainly related to skin reactions. Overall, 22 patients
(67%) reported adverse skin reactions, predominantly consisting of
a dry, erythematous, itching or painful skin, sometimes accompa-
nied by desquamation. In most patients, skin reactions occurred
after 3 weeks of treatment. The maximum intensity was ￿slight￿ in
five cases, ￿moderate￿ in 15, ￿severe￿ in one and not documented in
one case. With regard to these skin reactions, transient treatment
modifications, such as reducing the frequency of application or a
treatment-free interval of usually a week, were made in 15 patients.
In four of these patients the frequency of application was reduced to
once daily, in four patients the miltefosine treatment was
temporarily stopped and in seven patients both measures were
taken. In two patients adverse skin reactions contributed to the
decision to discontinue the treatment. Nausea was observed in two
patients (6%). It should be noted, however, that the treated area in
these two patients was limited (19 cm2 and 2 cm2), which virtually
excludes the possibility of a critical systemic uptake of miltefosine.
Haematotoxic or blood chemistry changes were not observed.
Response
Three patients received concomitant systemic tumour therapy
and were excluded from response evaluation. Thirty patients
were therefore assessable for therapeutic efficacy. The overall
response rate (complete response + partial response) was 13/30
(43%), seven of which were complete (23%) and six of which
were partial (20%). An example of a patient treated with miltefo-
sine is shown in Figures 2—5. Stable disease was seen in 10/30
patients (33%) and 7/30 (23%) showed progression. The median1160 JMM Terwogt et al
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Table 1 Patient characteristics
Patient characteristics No. %
Total patients 33 100
Evaluable for toxicity 33 100
Evaluable for anti-tumour activity 30 91
Median age, years (range) 57 (30–90)
WHO performance status
0 21 64
1 10 30
2 13
Not documented 1 3
Pretreatment combination
Surgery + endocrine therapy 2 6
Surgery + endocrine therapy + chemotherapy 1 3
Surgery + radiation + chemotherapy 1 3
Surgery + radiation + endocrine therapy 6 18
Radiation + endocrine therapy + chemotherapy 8 24
Surgery + radiation + endocrine therapy + chemotherapy 15 45
Time (years) between first diagnosis and start of miltefosine treatment
≤ 4 14 42
5–8 10 30
9–12 26
> 12 72 1
Time (months) between first occurrence of skin metastases and start
of miltefosine treatment
≤ 6 51 5
7–12 26
13–24 7 21
25–48 11 33
> 48 82 4
Figures 2–5 The figures depict skin deposits in a previously irradiated breast of a 53-year-old woman, who presented with inflammatory breast cancer and was
treated with anthracycline-based primary chemotherapy. Diagnosis was confirmed by biopsy (black scar in Figures 2 and 3) and she was treated with 8 weeks
miltefosine. The treated area shows white discolouration in Figures 4 and 5. Outside the treated area (below the nipple) new skin deposits have developed. These
lesions were treated successfully with miltefosine, but other systemic treatment became necessary by rapidly progressive lung metastases. She died 8 months later
Figure 2 Figure 3
Figure 4 Figure 5Topical miltefosine in skin-metastasized breast cancer 1161
British Journal of Cancer (1999) 79(7/8), 1158–1161 © Cancer Research Campaign 1999
response duration was 18 weeks, range 8—68. In Table 2 response
duration is specified according to response.
DISCUSSION AND CONCLUSION
The topical administration of a cytotoxic drug offers a new
approach to the treatment of metastatic skin deposits from breast
cancer. A major advantage of this administration route is the
reduced risk of systemic toxicity. Furthermore, the drug is easily
applied by the patient, eliminating the need for hospitalization
(Unger et al, 1990). Several factors such as chemical structure and
lipid solubility determine whether a cytotoxic drug will penetrate
the skin. Compounds that have a well-balanced water and lipid
solubility are in general good penetrants (Unger et al, 1992).
Miltefosine is a cytotoxic agent with such favourable characteris-
tics and with proven activity in breast cancer (Hilgard et al, 1988;
Eibl and Unger, 1990; Fichtner et al, 1994). To further increase
penetration, miltefosine is dissolved in a mixture of short-chain
glycerolethers. The resulting oily solution can easily be applied to
the skin.
In this study of 33 patients with skin lesions from breast
cancer, miltefosine showed promising therapeutic activity. A total
response rate (complete response + partial response) of 43% was
observed. Comparable results were obtained by Clive and Leonard
(1997). The topical administered lotion of miltefosine was
frequently (22/33; 67%) accompanied by localized adverse skin
reactions but these were usually of mild to moderate intensity
(20/22; 91%). Moreover, because these reactions were visible,
they were readily managed by reducing the frequency of applica-
tion (from twice to once daily administration) or by stopping treat-
ment temporarily. Compatible with the results from other studies
(Unger et al, 1988, 1990, 1992; Detmar et al, 1994; Clive and
Leonard, 1997) we found that systemic toxicity of miltefosine,
even after extensive topical treatment, was negligible. Therefore,
we conclude that topical administration of miltefosine is an effec-
tive treatment to control temporarily breast cancer skin lesions,
either in systemically pretreated patients or as a measure to post-
pone the more aggressive systemic chemotherapy. Under the
investigational setting the treatment was discontinued as soon as
new (systemic) therapy due to progression of the disease was
started. However, continuation of the topical treatment or retreat-
ment in case of relapse might be considered outside clinical
trials. The figures in this study are too small to draw a firm conclu-
sion on which lesions are the best suitable for miltefosine treat-
ment; however, flat non-ulcerative intracutaneous lesions seem to
respond the best.
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Table 2 Response
Response Number of patients (%) Median duration of response in weeks (range)
Complete remission 7 (23) 24 (8–68)
Partial remission 6 (20) 12 (8–22)
Stable disease 10 (33) 8 (6–13)
Progressive disease 7 (23)